Student and Student Athlete Opioid Misuse Prevention Act This bill authorizes the Substance Abuse and Mental Health Services Administration (SAMHSA) to provide grants to support addiction-prevention and prescription-drug-misuse programs related to opioids and other medications used for pain or injury recovery. Specifically, SAMHSA may award grants to eligible public and nonprofit private entities, including states and drug-free community coalitions, to carry out such programs in schools, athletic programs, and communities. Among other activities, grant recipients may use funds to educate teachers, campus-based medical providers, and others on signs of opioid misuse and options for treatment and prevention. In addition, SAMHSA must report annually on federal programs to prevent pain medication misuse and addiction.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
AthletesChild healthDrug, alcohol, tobacco useDrug trafficking and controlled substancesHealth programs administration and fundingHealth promotion and preventive carePrescription drugsSchool athletics
Student and Student Athlete Opioid Misuse Prevention Act
USA116th CongressS-3222| Senate
| Updated: 1/21/2020
Student and Student Athlete Opioid Misuse Prevention Act This bill authorizes the Substance Abuse and Mental Health Services Administration (SAMHSA) to provide grants to support addiction-prevention and prescription-drug-misuse programs related to opioids and other medications used for pain or injury recovery. Specifically, SAMHSA may award grants to eligible public and nonprofit private entities, including states and drug-free community coalitions, to carry out such programs in schools, athletic programs, and communities. Among other activities, grant recipients may use funds to educate teachers, campus-based medical providers, and others on signs of opioid misuse and options for treatment and prevention. In addition, SAMHSA must report annually on federal programs to prevent pain medication misuse and addiction.